Updates Center

• 
  A Wild Collection: The Most Unusual Species AtaGenix Has Worked With

  Since 2011, AtaGenix has delivered one-stop custom solutions for over 100 species worldwide. This article presents verified cases from Nature Communications, Nature Genetics, and other top journals, systematically demonstrating expertise in antibody development, protein production, and expression systems across plants (rice, chili), mammals (mouse, chicken), insects (diamondback moth), aquatic organisms (grass carp, shrimp), fungi (Mycobacterium tuberculosis), and parasites (Cryptosporidium), embodying truly “boundless” research customization.
• 
  AtaGenix October 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  In October 2025, AtaGenix delivered critical antibody solutions for seven groundbreaking studies published in Cell (IF 42.5), Nature Plants (IF 13.6), and other leading journals. Research spanned insect endosymbiont tubenets, Bacteroidota T6SS co-secretion, Brassica pancentromere dynamics, lysosomal damage in Duchenne muscular dystrophy, and more. Custom anti-Lpp, CENH3, SiFBA4, and anti-R99me2a antibodies enabled immunogold labeling, ChIP-seq, protein quantification, and translational regulation studies—overcoming key experimental hurdles. Over 500 SCI papers have now cited AtaGenix’s one-stop protein and antibody development platform. The ongoing literature reward program continues to incentivize citations.
• 
  AtaGenix September 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  The AtaGenix September 2025 Literature Collection highlights the company’s pivotal role in supporting groundbreaking life science research. Featuring studies published in high-impact journals like Journal of Nanobiotechnology and Cell Reports, this collection showcases advancements in lipid nanoparticle-based mRNA vaccines, gastric cancer drug resistance mechanisms, LayV virus antigenicity, jujube centromere evolution, and tomato plant vigor regulation. AtaGenix’s technical services, including custom antibodies and hybridoma screening tools, were instrumental in these discoveries, reinforcing its commitment to driving innovation in life sciences.
• 
  VINS Visits AtaGenix Wuhan HQ for Biopharma Partnership

  On June 25, 2025, VINS Bioproducts visited AtaGenix’s Wuhan headquarters to expand collaboration on vaccine raw materials, antibody R&D, and CRO services—advancing public health and innovation.
• 
  AtaGenix Excels at Thailand LAB International 2025: Pioneering Antibody Discovery & Protein Expression

  AtaGenix Laboratories Co., Ltd. participated in Thailand LAB International 2025 in Bangkok from September 3-5, showcasing advanced antibody discovery and protein expression technologies at booth 2S21. Through technical exhibits, seminars, and business discussions, AtaGenix established global partnerships, reinforcing its leadership in the Asia-Pacific biotechnology market.
• 
  Meet AtaGenix at LAB International Thailand 2025 | Booth 2S21 | September Exhibition

  AtaGenix will participate in LAB International 2025, taking place in Thailand from September 3 to 5, 2025. Visit Booth 2S21 to explore our capabilities in antibody discovery, engineering, protein expression, and purification, as well as the abinScience portfolio of recombinant proteins and antibodies. Let’s connect and discuss potential collaborations.
• 
  BioTAG Visits AtaGenix Headquarters to Advance Antibody Drug Development and Precision Medicine

  On August 13, 2025, BioTAG from Israel visited AtaGenix’s Wuhan headquarters to discuss antibody drug development, protein engineering, and CRO services. The collaboration aims to advance precision medicine and biopharmaceutical innovation globally.
• 
  Antibody Discovery Paradigm Shift: Single B-Cell Cloning Challenges Phage Display Dominance

  single B-cell cloning, phage display, antibody discovery, native VH VL pairing, antibody development trends, hybridoma sequencing, nanobody, multispecific antibody, AtaGenix
• 
  First Commercial Bispecific ADC Projected by 2029 — Pipeline Tops 100 Clinical Candidates

  bispecific ADC, BsADC, antibody-drug conjugate, bispecific antibody, multispecific biologics, oncology pipeline, ADC linker payload, site-specific conjugation, China biopharma, AtaGenix
• 
  Global Antibody Discovery Market to Soar from USD 1.9B in 2024 to USD 3.3B by 2030

  The global antibody discovery market, valued at USD 1.9 billion in 2024, is projected to reach USD 3.3 billion by 2030, with a CAGR of 9.8%. Growth is fueled by expanding pipelines in monoclonal antibodies, rapid adoption of bispecifics, and increasing investment in antibody–drug conjugates (ADCs). Advances in single B-cell technologies, AI-driven design, and stable cell line development are accelerating discovery and reducing development risks. As demand rises for next-generation biologics, AtaGenix provides integrated discovery, screening, and engineering platforms to help researchers and partners achieve faster, cost-effective progress.